

# Yu-Long Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10943748/publications.pdf>

Version: 2024-02-01

16  
papers

444  
citations

759233

12  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

757  
citing authors

#	ARTICLE	IF	CITATIONS
1	Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. <i>Journal of Medical Genetics</i> , 2013, 50, 689-695.	3.2	66
2	Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence. <i>Thyroid</i> , 2017, 27, 537-545.	4.5	56
3	Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 120-132.	3.6	42
4	Association between the rs2910164 Polymorphism in Pre-Mir-146a Sequence and Thyroid Carcinogenesis. <i>PLoS ONE</i> , 2013, 8, e56638.	2.5	37
5	Association of the miR-149 Rs2292832 Polymorphism with Papillary Thyroid Cancer Risk and Clinicopathologic Characteristics in a Chinese Population. <i>International Journal of Molecular Sciences</i> , 2014, 15, 20968-20981.	4.1	34
6	Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: Experience of one cancer center 1997-2007. <i>Acta Oto-Laryngologica</i> , 2012, 132, 1-8.	0.9	32
7	Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1269-1278.	4.5	27
8	The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial. <i>Thyroid</i> , 2021, 31, 1808-1813.	4.5	27
9	Predictive index for lymph node management of major salivary gland cancer. <i>Laryngoscope</i> , 2012, 122, 1497-1506.	2.0	26
10	Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy. <i>Cancer Medicine</i> , 2018, 7, 285-296.	2.8	23
11	Incidentally simultaneous occurrence of RET/PTC, H4PTEN and BRAF mutation in papillary thyroid carcinoma. <i>Cancer Letters</i> , 2008, 263, 44-52.	7.2	21
12	Significant SNPs have limited prediction ability for thyroid cancer. <i>Cancer Medicine</i> , 2014, 3, 731-735.	2.8	15
13	Clinical significance of papillary thyroid cancer risk loci identified by genome-wide association studies. <i>Cancer Genetics</i> , 2015, 208, 68-75.	0.4	14
14	Lymph node ratio (LNR) as a complementary staging system to TNM staging in salivary gland cancer. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 3425-3434.	1.6	9
15	IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro. <i>Journal of Cancer</i> , 2020, 11, 4250-4260.	2.5	9
16	Silencing of PPM1D inhibits cell proliferation and invasion through the p38 $\frac{1}{2}$ MAPK and p53 signaling pathway in papillary thyroid carcinoma. <i>Oncology Reports</i> , 2020, 43, 783-794.	2.6	6